These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 14670324)

  • 21. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.
    McBride BW; Mogg A; Telfer JL; Lever MS; Miller J; Turnbull PC; Baillie L
    Vaccine; 1998 May; 16(8):810-7. PubMed ID: 9627938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
    Williamson ED; Hodgson I; Walker NJ; Topping AW; Duchars MG; Mott JM; Estep J; Lebutt C; Flick-Smith HC; Jones HE; Li H; Quinn CP
    Infect Immun; 2005 Sep; 73(9):5978-87. PubMed ID: 16113318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
    Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
    Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
    Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
    Domínguez-Castillo RI; Verma A; Amador-Molina JC; Sirota L; Arciniega JL
    Biologicals; 2013 Mar; 41(2):111-4. PubMed ID: 23137818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an in vitro-based potency assay for anthrax vaccine.
    Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP
    Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis.
    Yin Y; Zhang J; Dong D; Liu S; Guo Q; Song X; Li G; Fu L; Xu J; Chen W
    Vaccine; 2008 Oct; 26(46):5814-21. PubMed ID: 18786589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of protective immunity against lethal anthrax challenge with a patch.
    Kenney RT; Yu J; Guebre-Xabier M; Frech SA; Lambert A; Heller BA; Ellingsworth LR; Eyles JE; Williamson ED; Glenn GM
    J Infect Dis; 2004 Aug; 190(4):774-82. PubMed ID: 15272406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.
    Weiss S; Kobiler D; Levy H; Marcus H; Pass A; Rothschild N; Altboum Z
    Infect Immun; 2006 Jan; 74(1):394-8. PubMed ID: 16368995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
    Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
    Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
    Corey A; Migone TS; Bolmer S; Fiscella M; Ward C; Chen C; Meister G
    Toxins (Basel); 2013 Jan; 5(1):120-38. PubMed ID: 23344456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc
    Song X; Zhang W; Zhai L; Guo J; Zhao Y; Zhang L; Hu L; Xiong X; Zhou D; Lv M; Yang W
    Front Immunol; 2022; 13():819089. PubMed ID: 35154137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.
    Bellanti JA; Lin FY; Chu C; Shiloach J; Leppla SH; Benavides GA; Karpas A; Moayeri M; Guo C; Robbins JB; Schneerson R
    Clin Vaccine Immunol; 2012 Feb; 19(2):140-5. PubMed ID: 22190398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
    Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W
    BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
    Stokes MG; Titball RW; Neeson BN; Galen JE; Walker NJ; Stagg AJ; Jenner DC; Thwaite JE; Nataro JP; Baillie LW; Atkins HS
    Infect Immun; 2007 Apr; 75(4):1827-34. PubMed ID: 17145938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.
    Henning LN; Carpenter S; Stark GV; Serbina NV
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.